Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P55273

UPID:
CDN2D_HUMAN

ALTERNATIVE NAMES:
p19-INK4d

ALTERNATIVE UPACC:
P55273; Q13102; Q6FGE9

BACKGROUND:
The protein Cyclin-dependent kinase 4 inhibitor D, known alternatively as p19-INK4d, serves as a critical regulator of the cell cycle. It achieves this by strongly interacting with and inhibiting CDK4 and CDK6, enzymes essential for cell cycle progression. This inhibition is a key mechanism by which the cell ensures proper timing of division and growth, highlighting the protein's importance in maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cyclin-dependent kinase 4 inhibitor D's function offers a promising avenue for therapeutic intervention. Given its central role in regulating cell division by modulating CDK4 and CDK6 activity, targeting this protein could provide a novel approach to managing diseases characterized by abnormal cell proliferation, such as cancer. Advancing our understanding of its regulatory mechanisms could be instrumental in the development of innovative cancer treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.